Stockreport

Sorrento Therapeutics Announces the Initiation of Dosing in Its Anti-CD38 CAR-T Phase 1 Clinical Study for Relapsed or Refractory Multiple Myeloma

Sorrento Therapeutics, Inc.  (SRNE) 
Last sorrento therapeutics, inc. earnings: 8/9 04:49 pm Check Earnings Report
US:NASDAQ Investor Relations: sorrentotherapeutics.com/investors
PDF SAN DIEGO, Nov. 01, 2018 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (NASDAQ: SRNE), an innovative immunotherapy company, announced today that the first patients w [Read more]